Welcome to the Lupus Educators' Network

Explore educational content from our robust network of experts supporting our commitment to SLE and LN

chart icon

SLE is a disease of waxing 
and waning activity and progressive organ damage; 
a critical goal in the 
management of SLE is to reduce organ damage accrual1

icon scales

SLE is ~9x more prevalent in females than males2, and disproportionally affects racial/ethnic minority groups who have earlier onset of severe manifestations of SLE, such as LN3

Icon 50percent

Approximately

30to50 percent

experience organ damage within 5 years of diagnosis4-7

Icon 40percent

 

~20% of patients with LN 
will progress to ESKD within 
10 years of diagnosis9

Icon framework

Disease modification framework:

Reducing disease activity 
with the fewest treatment-associated toxicities and slowing or preventing irreversible organ damage10

Icon chart

SLE management goals11,12:

Consider applying a disease modification mindset with shared decision-making to improve patient outcomes

Hear from Our Lupus Experts

Use filter(s) to narrow selection

The Importance of Timely referrals to Nephrology for Suspected Renal Involvement in SLE Podcast

Dr. R. Raghavan

  • Podcast
  • • 6:30

Applying the Lupus Disease Modification Framework to Slow Organ Damage Progression: A Representative Patient Case

Dr. M. Dall'Era

  • Video
  • • 20:44

Screening Mishaps in Lupus Nephritis Kidney Progression

Dr. R. Raghavan

  • Video
  • • 11:34

EULAR 2023 Recommendations Podcast

Dr. N. Annapureddy

  • Podcast
  • • 7:54

Changing the Course of Disease in Lupus

Dr. A. Askanase and Dr. R. Raghavan

  • Video
  • • 4:47

How the 2023 EULAR Recommendations Could Shift the Management of Lupus Care

Dr. M. Dall'Era

  • Video
  • • 3:59

Perhaps It's Lupus: The Importance of Early Diagnosis and Management of SLE in Individuals of African Descent

Dr. A. Blazer

  • Video
  • • 12:23

Addressing Health Disparities in Lupus Nephritis

Dr. A. Blazer and Dr. H. Menn-Josephy

  • Video
  • • 9:51

LN: Through the Patient Lens

Dr. H. Menn-Josephy and Dr. R. Levy

  • Video
  • • 28:02

Clinical Utility of eGFR Slope as a Surrogate Endpoint in Lupus Nephritis and ESKD

Dr. J. Radhakrishnan

  • Video
  • • 4:55

Complete Renal Response

Dr. Michelle Petri

  • Video
  • • 9:34

Roadblocks to Reaching Remission in SLE

Dr. Michelle Petri

  • Video
  • • 12:06

Slowing SLE Organ Damage Progression: The Importance of Optimal & Equitable Care

Dr. A. Askanase and Dr. A. Blazer

  • Video
  • • 15:16

A Call for Early SLE Intervention in Minoritized Patients

Dr. A. Blazer

  • Podcast
  • • 5:08

Takeaways from Recent LN Clinical Practice Recommendations

Dr. R. Raghavan

  • Podcast
  • • 7:06

The Importance of Preventing Kidney Flares in Lupus Nephritis

Dr. R. Raghavan

  • Podcast
  • • 7:11

Organ Damage in SLE, More Than Just the Kidneys

Dr. A. Blazer

  • Video
  • • 4:02

Early Initiation of Biologics and Organ Damage: The Right Time

Dr. A. Crowley

  • Video
  • • 4:39

Family Planning in SLE and LN: Starting Before Pregnancy

Dr. A. Blazer

  • Video
  • • 8:29

Explore SLE

Use filter(s) to narrow selection

The Importance of Timely referrals to Nephrology for Suspected Renal Involvement in SLE Podcast

Dr. R. Raghavan

  • Podcast
  • • 6:30

How the 2023 EULAR Recommendations Could Shift the Management of Lupus Care

Dr. M. Dall'Era

  • Video
  • • 3:59

EULAR 2023 Infographic

  • Infographic

Perhaps It's Lupus: The Importance of Early Diagnosis and Management of SLE in Individuals of African Descent

Dr. A. Blazer

  • Video
  • • 12:23

Changing the Course of Disease in Lupus

Dr. A. Askanase and Dr. R. Raghavan

  • Video
  • • 4:47

Slowing SLE Organ Damage Progression: The Importance of Optimal & Equitable Care

Dr. A. Askanase and Dr. A. Blazer

  • Video
  • • 15:16

Biologics Mini-Session (The Potential for Biologics to Change the Course of Disease in Lupus)

  • Video
  • • 6:07

Roadblocks to Reaching Remission in SLE

Dr. Michelle Petri

  • Video
  • • 12:06

Complete Renal Response

Dr. Petri

  • Video
  • • 9:34

Biologics Mini-Session (Addressing Unmet Needs, Treatment Goals, and Disease Modification in Lupus)

  • Video
  • • 8:47

Biologics Mini-Session (Exploring Earlier Use of Biologics in SLE: A Patient Case Study)

  • Video
  • • 4:30

EULAR 2023 Recommendations Podcast

Dr. N. Annapureddy

  • Podcast
  • • 7:54

Applying the Lupus Disease Modification Framework to Slow Organ Damage Progression: A Representative Patient Case

Dr. M. Dall'Era

  • Video
  • • 20:44

SLE Mechanism of Disease

  • Video
  • • 4:18

A Call for Early SLE Intervention in Minoritized Patients

Dr. A. Blazer

  • Podcast
  • • 5:08

Organ Damage in SLE, More Than Just the Kidneys

Dr. A. Blazer

  • Video
  • • 4:02

Early Initiation of Biologics and Organ Damage: The Right Time

Dr. A. Crowley

  • Video
  • • 4:39

Family Planning in SLE and LN: Starting Before Pregnancy

Dr. A. Blazer

  • Video
  • • 8:29

Integrating Social Determinants of Health (SDOH) into Lupus Care Strategies

  • Infographic
Close
Copy URL

Abbreviations

ESKD = end-stage kidney disease; LN = lupus nephritis; SLE = systemic lupus erythematosus; US = United States.

References

  1. Thanou A, et al. J Autoimmun. 2021;119:102615.
  2. Izmirly PM, et al. Arthritis Rheumatol. 2021;73(6):991-996.
  3. Maningding E, et al. Arthritis Care Res (Hoboken). 2020;72(5):622-629.
  4. Chambers SA, et al. Rheumatology (Oxford). 2009;48(6):673-675.
  5. Urowitz MB, et al. Arthritis Care Res (Hoboken). 2012;64(1):132-137.
  6. Frodlund M, et al. Lupus. 2019;28(10):1261-1272.
  7. Segura BT, et al. Rheumatology (Oxford). 2020;59(3):698.
  8. Morales E, et al. Nephron. 2021;145(1):1-13.
  9. Tektonidou MG, et al. Arthritis Rheumatol. 2016;68(6):1432-1441.
  10. van Vollenhoven R, et al. Lupus Sci Med. 2022;9(1):e000634.
  11. American College of Rheumatology. 2025 American College of Rheumatology Guideline for the Treatment of Systemic Lupus Erythematosus (SLE): Guideline Summary. May 7, 2025. Accessed September 12, 2025. https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltec93920aad624e33/sle-guideline-summary-2025.pdf
  12. Sammaritano LR, et al. Arthritis Rheumatol. 2025;77(9):1115-1135.